The potential for local ablative therapy of oligometastases in head and neck squamous cell carcinoma: a real-world data analysis

References

• Kjems J, Zukauskaite R, Johansen J, et al. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. Acta Oncol. 2021;60(11):1472–1480. doi: 10.1080/0284186X.2021.1959056.
   PubMed Web of Science ®Google Scholar
• Duprez F, Berwouts D, De Neve W, et al. Distant metastases in head and neck cancer. Head Neck. 2017;39(9):1733–1743. doi: 10.1002/hed.24687.
   PubMed Web of Science ®Google Scholar
• Moon DH, Sher DJ. Oligometastasis in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2022;114(4):803–811. doi: 10.1016/j.ijrobp.2022.06.086.
   PubMed Web of Science ®Google Scholar
• Vengaloor Thomas T, Packianathan S, Bhanat E, et al. Oligometastatic head and neck cancer: comprehensive review. Head Neck. 2020;42(8):2194–2201. doi: 10.1002/hed.26144.
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8.
   PubMed Web of Science ®Google Scholar
• Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–166. doi: 10.1016/j.radonc.2020.04.003.
   PubMed Web of Science ®Google Scholar
• Young ER, Diakos E, Khalid-Raja M, et al. Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin Otolaryngol. 2015;40(3):208–218. doi: 10.1111/coa.12348.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi: 10.1016/S0140-6736(18)32487-5.
   PubMed Web of Science ®Google Scholar
• Bonomo P, Greto D, Desideri I, et al. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: is the deferral of systemic therapy a potential goal? Oral Oncol. 2019;93:1–7. doi: 10.1016/j.oraloncology.2019.04.006.
   PubMed Web of Science ®Google Scholar
• Chalkidou A, Macmillan T, Grzeda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. doi: 10.1016/S1470-2045(20)30537-4.
   PubMed Web of Science ®Google Scholar
• Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–2970. doi: 10.1002/cncr.26611.
   PubMed Web of Science ®Google Scholar
• Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–886. doi: 10.1016/j.ijrobp.2011.08.036.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Jovanovic A, Godballe C, et al. The Danish head and neck cancer database. Clin Epidemiol. 2016;8:491–496. doi: 10.2147/CLEP.S103591.
   PubMed Web of Science ®Google Scholar
• Schulz D, Wirth M, Piontek G, et al. Improved overall survival in head and neck cancer patients after specific therapy of distant metastases. Eur Arch Otorhinolaryngol. 2018;275(5):1239–1247. doi: 10.1007/s00405-018-4920-9.
   PubMed Web of Science ®Google Scholar
• de Bree R, Senft A, Coca-Pelaz A, et al. Detection of distant metastases in head and neck cancer: changing landscape. Adv Ther. 2018;35(2):161–172. doi: 10.1007/s12325-018-0662-8.
   PubMed Web of Science ®Google Scholar
• Risør LM, Loft A, Berthelsen AK, et al. FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy. Eur Arch Otorhinolaryngol. 2020;277(2):539–547. doi: 10.1007/s00405-019-05684-2.
   PubMed Web of Science ®Google Scholar
• Bøje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma – a systematic review. Radiother Oncol. 2014;110(1):81–90. doi: 10.1016/j.radonc.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637. doi: 10.1016/S1470-2045(15)70168-3.
   PubMed Web of Science ®Google Scholar
• Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer: long-term results of the single-arm STARS prospective trial. Lancet Oncol. 2021;22(10):1448–1457. doi: 10.1016/S1470-2045(21)00401-0.Stereotactic.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi: 10.1016/S1470-2045(19)30718-1.
   PubMed Web of Science ®Google Scholar